Silverman Joshua 4
4 · PharmaCyte Biotech, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Silverman Joshua
DirectorCEO and President
Transactions
- Purchase
Common Stock
2026-01-05$0.78/sh+30,000$23,493→ 346,250 total - Purchase
Common Stock
2026-01-06$0.79/sh+30,000$23,667→ 376,250 total - Purchase
Common Stock
2026-01-07$0.83/sh+40,000$33,316→ 416,250 total
Holdings
- 50,000(indirect: By LLC)
Common Stock